Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

被引：0
|
作者：
Modar Khalil
Hassan W Zafar
Victoria Quarshie
Fayyaz Ahmed
机构：
[1] Hull Royal Infirmary,Specialist Registrar in Neurology
[2] Hull Royal Infirmary,Specialist Headache Nurse
[3] Consultant Neurologist,undefined
[4] Hull Royal Infirmary,undefined
来源：
The Journal of Headache and Pain | 2014年 / 15卷
关键词：
Migraine; National Health Service; Chronic Migraine; Medication Overuse; Episodic Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
    Katja Kollewe
    Charly Gaul
    Astrid Gendolla
    Katherine Sommer
    The Journal of Headache and Pain, 2021, 22
  • [42] Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
    Kollewe, Katja
    Gaul, Charly
    Gendolla, Astrid
    Sommer, Katherine
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [43] Efficacy of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Cheng, F.
    Hussain, M.
    Wilkinson, V.
    Khalil, M.
    Ahmed, F.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 262 - 262
  • [44] Efficacy of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
    Cheng, F.
    Hussain, M.
    Wilkinson, V.
    Khalil, M.
    Ahmed, F.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [45] Five year outcome on 310 patients receiving OnabotulinumtoxinA for Chronic Migraine; data from Hull Migraine Clinic
    Ahmed, Fayyaz
    Buture, Alina
    Tanvir, Taukir
    Khalil, Modar
    CEPHALALGIA, 2019, 39 : 274 - 274
  • [46] FIVE YEAR OUTCOME ON 211 PATIENTS RECEIVING ONABOTULINUMTOXINA FOR CHRONIC MIGRAINE; DATA FROM HULL MIGRAINE CLINIC
    Ahmed, F.
    Khalil, M.
    Tanvir, T.
    Buture, A.
    CEPHALALGIA, 2018, 38 : 86 - 87
  • [47] Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
    Raffaele Ornello
    Simona Guerzoni
    Carlo Baraldi
    Luana Evangelista
    Ilaria Frattale
    Carmine Marini
    Cindy Tiseo
    Francesca Pistoia
    Simona Sacco
    The Journal of Headache and Pain, 2020, 21
  • [48] Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
    Ornello, Raffaele
    Guerzoni, Simona
    Baraldi, Carlo
    Evangelista, Luana
    Frattale, Ilaria
    Marini, Carmine
    Tiseo, Cindy
    Pistoia, Francesca
    Sacco, Simona
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [49] DOES MEDICATION OVERUSE MATTER? RESPONSE TO ONABOTULINUMTOXINA IN CHRONIC MIGRAINE (CM) PATIENTS WITH OR WITHOUT MEDICATION OVERUSE; UPDATE FROM REAL-LIFE DATA
    Ahmed, F.
    Khalil, M.
    Tanvir, T.
    Buture, A.
    CEPHALALGIA, 2018, 38 : 85 - 86
  • [50] Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
    Raffaele Ornello
    Fayyaz Ahmed
    Andrea Negro
    Anna Maria Miscio
    Antonio Santoro
    Alicia Alpuente
    Antonio Russo
    Marcello Silvestro
    Sabina Cevoli
    Nicoletta Brunelli
    Fabrizio Vernieri
    Licia Grazzi
    Carlo Baraldi
    Simona Guerzoni
    Anna P. Andreou
    Giorgio Lambru
    Katharina Kamm
    Ruth Ruscheweyh
    Marco Russo
    Paola Torelli
    Elena Filatova
    Nina Latysheva
    Anna Gryglas-Dworak
    Marcin Straburzyński
    Calogera Butera
    Bruno Colombo
    Massimo Filippi
    Patricia Pozo-Rosich
    Paolo Martelletti
    Simona Sacco
    Pain and Therapy, 2021, 10 : 1605 - 1618
12345